Reticulocyte invasion by Plasmodium vivax and Plasmodium knowlesi requires binding of the Duffy-binding protein (known as PvDBP or PkDBP, respectively, in the two species) to the red blood cell (RBC) Duffy antigen receptor for chemokines (DARC) [1] [2] [3] . PvDBP is a leading vaccine target candidate for P. vivax malaria because the absence of PvDBP-DARC interaction in Duffy-null individuals confers protection against P. vivax infection 3 . Understanding the structure, function and mechanism of this important receptor-ligand interaction may inform strategies for improved control. PvDBP contains a single 302-amino-acid cysteine-rich Duffy binding-like (DBL) domain within its extracellular N terminus, known as region II (RII-PvDBP) 4 , that includes 12 conserved cysteines and is sufficient for binding to DARC 5, 6 .
response and for immune evasion by the parasite, the molecular basis for protection and immune evasion are unclear.
Here, we present the crystal structure of the clinically relevant RII-PvDBP, show that RII-PvDBP dimerization is required for receptor binding, and demonstrate that receptor binding drives RII-PvDBP dimerization in solution. The structure reveals a putative DARC-binding site and putative sulfotyrosine-binding pocket formed by a RII-PvDBP dimer. Both are distinct from residues previously thought to bind sulfotyrosine 24 . The dimer interface and critical DARC-binding residues required for RBC binding are targeted by the immune response and are structurally and functionally conserved. These results elucidate the molecular mechanism of DBL-receptor interactions and identify new targets for smallmolecule and vaccine therapeutics.
RESULTS

Overall architecture of the RII-PvDBP homodimer
The single DBL domain from PvDBP (RII-PvDBP) is sufficient for binding to DARC 5, 6 . We have determined a 1.95-Å crystal structure of RII-PvDBP (Fig. 1, Supplementary Fig. 2 and Table 1 ). The DBL domain RII-PvDBP is shaped like an elongated boomerang and composed primarily of α-helices, with an antiparallel β-hairpin near the N terminus. RII-PvDBP is similar in sequence and structure to the DBL domains of RII-PfEBA-175 and RII-PkDBP, with r.m.s. deviations of 1.53, 1.84 and 1.06 Å, respectively (Supplementary Fig. 3 ). The RIIPvDBP DBL domain is composed of three subdomains that are stabilized by intra-subdomain disulfide bridges (Fig. 1a, Supplementary  Fig. 1b ). Subdomain 1 (S1) is composed of residues Asn211-Leu253 and has two intra-subdomain disulfides, Cys217-Cys246 and Cys230-Cys237. Subdomain 2 (S2) is composed of residues Tyr271-Glu386 and has one intra-subdomain disulfide, Cys300-Cys377. Subdomain 3 (S3) is composed of residues Pro387-Ser508 and has three intrasubdomain disulfides, Cys415-Cys432, Cys427-Cys507 and Cys436-Cys505 (Fig. 1a) . All cysteines in the DBL domain are involved in disulfide bridges, with a conserved disulfide bridging pattern seen in the DBL domains of P. falciparum EBA-175 (RII-PfEBA-175) and P. knowlesi DBP (RII-PkDBP) (Supplementary Fig. 1b) .
Two RII-PvDBP monomers are related by noncrystallographic symmetry, generating a dimer in the asymmetric unit (Fig. 1b,c) . The dimeric architecture is created by homodimer contacts across subdomain 2. As shown below, the dimeric organization is required for functional receptor binding. A cluster of hydrophobic homodimer contacts are made by Phe267 and Leu270 of chain A with Ile277, Tyr278, Val282 and Tyr363 of chain B. A salt bridge across the two monomers at the dimer interface is created by Arg274 and Glu249.
The dimer creates a putative sulfotyrosine-binding pocket DARC sulfation results in a change in K i of inhibition of RBC binding from micromolar to low nanomolar, indicating that sulfation is critical for receptor recognition and binding 18 . To identify putative sulfotyrosine-binding pockets, we cocrystallized RII-PvDBP with sodium selenate (Table 1) . Selenate is structurally similar to sulfate, so we reasoned that selenate should bind to and identify residues that form the sulfotyrosine-binding pocket. Selenate was also selected because selenium-anomalous data could be collected to unambiguously identify the selenate-binding sites.
We observed clear density at five sites in the anomalous maps for selenate at a sigma cutoff of >6. Of these five, two are located outside the minimal binding domain of RII-PvDBP and are likely not to be functionally relevant. The remaining three sites are at the dimer interface. In the native structure, two of these sites are occupied by phosphates. Because phosphate, selenate and sulfate are stereochemically similar, we propose that these phosphate-binding sites form a putative sulfotyrosine-binding pocket that binds sulfated DARC (Fig. 1d) . Lys273 and Gln356 of both chains and Arg274 of one chain create the pocket by directly contacting the selenates (Fig. 1d) . The putative sulfotyrosine-binding pocket is generated by the RII-PvDBP dimer and located in a positively charged groove at the dimer interface. We propose that this region is the DARC-binding groove that engages the highly acidic DARC (Fig. 1c) . a r t i c l e s 9 1 0 VOLUME 18 NUMBER 8 AUGUST 2011 nature structural & molecular biology a r t i c l e s Our structural studies suggest that an intact sulfotyrosine-binding pocket is critical for DARC-dependent binding of RBCs. We tested this model by mutating residues in the putative sulfotyrosine-binding pocket to alanine and assaying the ability of the mutants to bind RBCs in a rosette binding assay. Mutations of any residue in the putative sulfotyrosine-binding pocket resulted in a significant decrease in RBC rosetting (Fig. 1e,f and Supplementary Fig. 4 ). All decreases were significant as compared to wild type to P < 0.0001. These results are specific, as mutation of residues coordinating a third phosphate located away from the binding groove had no effect on rosetting ( Supplementary Fig. 4 ). These studies suggest that Lys273, Arg274 and Gln356 coordinate a DARC sulfotyrosine residue. Other regions of DARC would bind to the DARC-binding groove surrounding the putative sulfotyrosine-binding pocket at the dimer interface.
RBC binding is abolished and rescued by dimer mutations
Our structural studies show PvDBP must dimerize to create the DARC-binding groove and to bind RBCs. Arg274 and Glu249 form a salt bridge across two monomers at the dimer interface (Fig. 1e) . This salt bridge is on the opposite face of the putative sulfotyrosinebinding pocket and should not be involved in the DARC interaction. We found that RBC rosetting was abolished by a RII-PvDBP R274E mutation and partially restored in a double mutant with a second, compensatory mutation, RII-PvDBP R274E E249R ( Fig. 1f and Supplementary Fig. 4 ). These data demonstrate that disruption and restoration of the RII-PvDBP dimer interface with a salt bridge switch mutation abolishes and rescues RBC rosetting, and that the dimer architecture is required for RBC binding.
Notably, RII-PvDBP R274E E249R does not fully recapitulate wildtype function (Fig. 1f) because the asymmetric RII-PvDBP dimer contains two Arg274 residues in either the Arg274-Glu249 salt bridge or the DARC-binding groove on opposite sides of the RII-PvDBP homodimer (Fig. 1e) . This suggests that the complete loss of function in RII-PvDBP R274E is due to disruption of the wild-type dimer, which prevents formation of the DARC-binding site, and the ~50% restoration of function in RII-PvDBP R274E E249R is the result of a dimeric assembly with an incomplete putative sulfotyrosine-binding pocket. This is supported by data from the RII-PvDBP R274A mutant, which has ~50% functional activity due to the loss of Arg273 in the putative sulfotyrosine-binding pocket (Fig. 1f) .
DARC binding drives RII-PvDBP dimerization
The studies above demonstrate that both an intact sulfotyrosinebinding pocket and a correct dimer interface are required for receptor recognition leading to RBC attachment. We next wanted to establish the mechanism of receptor engagement and the effect of receptor binding on dimerization. We collected small-angle X-ray scattering (SAXS) data at several concentrations of RII-PvDBP in the presence and absence of unsulfated DARC . SAXS allows for the determination of molecular envelopes in solution and is an excellent tool to examine changes of oligomeric state during RII-PvDBP receptor recognition.
SAXS data for different concentrations of RII-PvDBP alone gave an excellent fit to predicted scattering of the crystal structure of monomeric RII-PvDBP at 1 mg ml −1 , with a χ 2 of 1.2, and a reasonable fit at 3 mg ml −1 , with a χ 2 of 3.89 (Fig. 2a, Supplementary Fig. 5a ). These χ 2 values were substantially lower than χ 2 values for fits to the dimer at each concentration, indicating that RII-PvDBP is monomeric at these concentrations. Ab initio modeling returned molecular envelopes that closely match the monomeric RII-PvDBP structure (Fig. 2a,b , inserts; Supplementary  Fig. 5 ). At 6 mg ml −1 , the experimental data for RII-PvDBP did not fit perfectly to calculated scattering from either the monomer or the dimer structures, suggesting that a mixture of both species was present (monomer χ 2 of 4.01, dimer χ 2 of 4.02; Fig. 2b ). Thus, RII-PvDBP alone is predominantly monomeric in solution at lower concentrations.
Notably, addition of DARC 1-60 drives dimerization of RII-PvDBP. SAXS data collected on an equimolar complex of RII-PvDBP and DARC 1-60 at 1, 3 and 6 mg ml −1 gave excellent fits to the RII-PvDBP dimer crystal structure, with χ 2 values of 2.17, 2.57 and 1.53, respectively (Fig. 2c,d, Supplementary Fig. 5b ). Molecular envelopes derived from ab initio modeling also revealed excellent fits to the dimeric RIIPvDBP structure (Fig. 2c,d, Supplementary Fig. 5b ). These data demonstrate that in solution DARC induces dimerization of RII-PvDBP, leading to the dimeric architecture observed in the crystal structure. This is especially evident when comparing the SAXS fits at 1 mg ml −1 (Fig. 2a,c) , as RII-PvDBP alone clearly fits to a monomer (monomer fit χ 2 = 1.2) whereas the RII-PvDBP-DARC complex is clearly dimeric (dimer fit χ 2 = 2.2). The dimeric architecture in the crystal structure is induced by phosphates or selenates binding in the putative sulfotyrosine-binding pocket mimicking DARC, whereas dimerization is induced in the solution studies by the addition of DARC .
To unambiguously determine the mass of the receptor-bound complex, we performed sedimentation-equilibrium analytical ultracentrifugation experiments. The molecular weight of the RII-PvDBP-DARC 1-60 complex was 90 ± 4 kDa (Supplementary Methods, Supplementary Fig. 6a ). This is consistent with a theoretical mass of 88.4 kDa for a complex of two RII-PvDBP and two DARC 1-60 molecules. To confirm our stoichiometry determination, we used isothermal titration calorimetry (ITC), as this technique directly measures stoichiometry as opposed to inferring stoichiometry from mass. a r t i c l e s Consistent with our SAXS and AUC measurements, ITC indicated that the complex has a stoichiometry of 1:1 RII-PvDBP and DARC ( Supplementary Methods, Supplementary Fig. 6b ).
Together, these results demonstrate that the receptor-bound complex contains two molecules of RII-PvDBP bound to two molecules of DARC . It is clear that the concentrations of full receptor and ligand required to induce dimerization and binding in vivo will be much lower than the range studied here, given that our experiments were performed on the isolated soluble RII-PvDBP domain and a small fragment of DARC (60 residues). Membrane anchoring of both PvDBP and DARC in vivo, in addition to the dimeric nature of DARC 16 , will increase the propensity to dimerize even further. Lastly, the addition of a sulfate group on DARC 1-60 is expected to further increase affinity for PvDBP and drive dimerization.
Functional regions of RII-PvDBP are under selective pressure
To visualize the effects of selective pressure on RII-PvDBP and test our receptor induced dimerization model, we mapped onto the structure known PvDBP polymorphisms and amino acid substitutions that affect RBC rosetting (Fig. 3a-c and Supplementary Fig. 7 ) 20, 23, 25, 26 . As the DARC-binding groove and RII-PvDBP dimer interface are functionally critical, receptor-induced dimerization predicts that functional regions will be underrepresented by polymorphic residues and overrepresented by residues essential for DARC recognition.
As expected, regions spanning the DARC-binding groove and dimer interface are devoid of documented polymorphic residues and heavily represented in essential residues (Fig. 3a-c and Supplementary Fig. 7) . Polymorphisms are spread across nonfunctional regions, suggesting that the parasite generates variations in nonfunctional residues spread throughout the DBL domain for immune evasion.
Blocking-antibodies target functional regions of RII-PvDBP
The humoral immune response has an important role during the pathogenesis of malaria. Receptor-induced dimerization predicts epitopes recognized by blocking antibodies against PvDBP will map to the DARC-binding groove or dimer interface. We mapped onto the structure epitopes targeted by blocking antibodies from sera of individuals with naturally acquired immunity to P. vivax ( Fig. 3d and  Supplementary Fig. 7 ) 22 . Five epitopes that correlated significantly (P < 0.05 (ref. 22)) with a block in PvDBP RBC rosetting are located in subdomain 2 of RII-PvDBP.
Mapping these five epitopes reveals that the DARC-binding groove and dimer interface are composed of the most significant epitope and surrounded by the four remaining epitopes (Fig. 3d and Supplementary  Fig. 7) . These results suggest that protective antibodies target functional regions in RII-PvDBP, leading to disruption of dimerization and/or prevention of receptor binding. Mapping blocking antibody epitopes onto PvDBP shows the importance of the DARC-binding groove and PvDBP dimerization in vivo and identifies structural regions targeted by the adaptive immune system in response to P. vivax. a r t i c l e s 170 residues of the 314-residue RII-PvDBP construct. Notably, this minimal binding domain retains all dimerization determinants and the putative sulfotyrosine-binding pocket, further indicating that the functional elements defined in this study are critical for DARC recognition ( Fig. 3e and Supplementary Fig. 7 ).
The minimal binding domain and asymmetric flap of RII-PvDBP
In the RII-PvDBP structure, residues 291-299 and 365-377 surround the DARC-binding groove (Fig. 3f,g ). In chain A, but not chain B, residues 365-377 are disordered, indicative of flexibility (Fig. 3f,g ). We therefore termed the region spanning residues 291-299 and 365-377 the asymmetric flap. These residues are not part of the putative sulfotyrosine-binding pocket but are required for DARC binding. Thus, we propose that these residues form a second DARC contact. DARC binding may stabilize the asymmetric flap to form a tight complex.
VAR2CSA shares the dimer interface and receptor-binding site
To test the generality of our receptor-mediated ligand-dimerization model, we examined receptor recognition by other DBL domains. The VAR2CSA variant of PfEMP1 is the primary virulence determinant for placental malaria and is associated with an estimated 75,000-200,000 infant deaths each year 28 . VAR2CSA is expressed on the surface of infected erythrocytes and binds specifically to chondroitin sulfate proteoglycans (CSPG) in the intervillous space of the placenta 29 . VAR2CSA contains six DBL domains, which can individually bind CSPG 30 . A recent study has reported the structure of VAR2CSA domain DBL6ε 31 ; the sixth DBL domain of VAR2CSA. DBL6ε crystallized with two copies in the asymmetric unit but was proposed to function as monomer, analogously to PkDBP.
We examined the crystal symmetry for the DBL6ε structure and found an unreported crystal-packing contact that is identical to RII-PvDBP's dimer interface (Fig. 4a) . Mutagenesis of several basic patches in DBL6ε identified two lysines, at positions 2392 and 2395, as essential for CSPG binding 31 . Notably, these lysines align to RIIPvDBP's putative sulfotyrosine-binding pocket (Fig. 4b) , with DBL6ε Lys2392 occupying the location of RII-PvDBP Arg274 and DBL6ε Lys2395 occupying the location of RII-PvDBP Lys273 (Fig. 4b) . Lys2395 is also close to an acidic residue on the opposing subunit at the dimer interface, in a configuration analogous to the Arg274-Glu249 salt bridge. Thus, DBL6ε may dimerize and bind its receptor in a manner similar to RII-PvDBP. Further examination of the oligomeric state of DBL6ε is warranted and could explain the greater receptor specificity and affinity of full-length VAR2CSA as compared to individual domains 30 .
DISCUSSION
In an effort to elucidate the molecular basis and mechanism of receptor recognition by PvDBP, we performed a structural, functional and mechanistic study of RII-PvDBP's interaction with the N terminus of DARC. We showed that RII-PvDBP's receptor-binding site is formed by a RII-PvDBP homodimer and that disruption and restoration of dimerization disrupts and restores RBC binding. We also demonstrated that dimerization is critical for, and driven by, receptor binding that leads to the formation of a complex composed of two PvDBP and two DARC. Finally, we showed that recognition of DARC occurs concomitantly with dimerization of PvDBP, placing the N termini of DARC in the DARC-binding groove created upon dimerization. Thus, receptor recognition by PvDBP is through receptor-mediated ligand dimerization (Fig. 5) . This model is applicable to receptor recognition by DBL domains from PvDBP, PfEMP1 VAR2CSA and PfEBA-175 (ref. 32) .
This model is consistent with structural and functional studies of PfEBA-175 that have proposed a dimeric RII-PfEBA-175 assembly upon receptor binding 32 . A subsequent crystal structure of RII-PkDBP from P. knowlesi DBP suggested that this domain binds to DARC as a monomer because no dimeric contacts were observed in the crystal structure 24 , which is inconsistent with the data presented here. It is likely that the RII-PkDBP structure is not dimeric, as these crystals were grown in detergent (0.5% N-octyl-β-d-glucopyranoside), which would disrupt biologically relevant oligomerization. Although the differences in the models may be due to interspecies differences, the structure of monomeric RII-PkDBP could represent the unbound monomer that dimerizes upon receptor binding.
Singh et al. further proposed a sulfotyrosine-binding pocket 24 , although no direct interaction studies were presented. Furthermore, the monomeric model of binding and the putative binding pocket cannot account for all mutations that affect binding to DARC reported in the literature 25, 26 . The authors also proposed a 'just-in-time release' strategy of immune evasion based on mapping of a subset of polymorphic residues to a face on the opposite side of their proposed DARCbinding site 24 . However, polymorphisms are more widely dispersed than those examined by Singh et al. 33 and cannot be accounted for by the monomeric model or just-in-time release strategy.
The receptor-mediated ligand dimerization model proposed here clarifies the mutational, polymorphism and antibody data for PvDBP. This model indicates that mutations can be grouped into residues that affect the dimer interface, the putative sulfotyrosine-binding pocket, the DARC-binding groove and the asymmetric flap. Our data strongly a r t i c l e s suggest an alternate location for the sulfotyrosine-binding pocket based on the identification of selenates and phosphates at the dimer interface coupled with functional studies. Field isolates of RII-PvDBP show extensive sequence polymorphism 20, 23 , which is thought to be an immune evasion mechanism. We have shown PvDBP immune evasion is mediated by generating polymorphisms in nonfunctional regions. Thus, immune evasion is achieved through changes at multiple regions, rather than through clustering of polymorphisms on one face of the DBL domain as previously proposed 24 . This method of immune evasion is similar to that proposed for influenzavirus hemagglutinin 34 . Notably, RIIPvDBP's putative sulfotyrosine-binding pocket, DARC-binding groove and dimer interface are all targeted by the adaptive immune response. Targeting these functional regions prevents RBC binding, thus leading to a protective immunity. These studies identify critical regions of RII-PvDBP that could be exploited for therapeutic design. Targeting the interaction between RII-PvDBP and DARC is effective against P. vivax, as natural selection of a Duffy-null phenotype has largely eliminated P. vivax in West Africa 3 .
In addition, PvDBP contains a region VI (RVI-PvDBP) with sequence similarity to region VI of PfEBA-175 (RVI-PfEBA-175, Supplementary Fig. 1 ). The crystal structure of RVI-PfEBA-175 showed that this domain dimerizes 35 , and the RVI-PvDBP domain is expected to increase the propensity of PvDBP to dimerize. Lastly, that membrane anchoring of both PvDBP and the DARC homodimer, and sulfation of DARC, are all likely to drive dimerization provides further support to the receptor-mediated ligand-dimerization model.
Receptor-mediated dimerization would increase the specificity and affinity of the host-parasite interaction. Ligand oligomerization during receptor binding has also been proposed for the Toxoplasma gondii micronemal proteins MIC3 (ref. 36 ) and MIC2 (ref. 37) . RBC invasion involves drastic changes within the merozoite, which would require intracellular signaling. Dimerization is common in signaling pathways 38 , and it is possible that receptor-induced liganddimerization of RII-PvDBP transduces a signal for initiation of RBC invasion. Finally, this model has implications for other chemokine receptor-ligand interactions that are reliant on sulfotyrosine, such as the HIV gp120-CCR5 interaction 39 .
We show that blocking antibodies prevent RBC binding by targeting epitopes at the dimer interface or in the DARC-binding groove, preventing dimerization and/or direct receptor binding. Our work provides structural details of RII-PvDBP regions relevant for vaccine design and predicts that focusing the immune response to the RII-PvDBP dimer interface and receptor-binding pocket epitopes could lead to the development of a potent neutralizing therapeutic. As receptor-mediated ligand dimerization is a general mechanism by which EBL proteins engage receptors, disrupting EBL dimerization could be a viable strategy for therapeutic intervention against other Plasmodium species.
Finally, these data show that single DBL domains dimerize upon receptor binding, consistent with studies on the multi-DBL domain proteins PfEBA-175 (ref. 32) and PfEMP1 (ref. 30) . This model for receptor recognition is applicable to the large superfamily of EBL proteins. We propose a mechanism of receptor-mediated ligand dimerization during the initiation of RBC invasion by Plasmodium parasites and upon receptor binding during PfEMP1-mediated cytoadherence and sequestration. This model allows for the possibility that induced dimerization activates downstream pathways essential for invasion. Finally, receptor-mediated ligand dimerization is expected to increase receptor specificity and affinity and may explain how DBL domains can recognize a wide variety of receptor chemistries.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/.
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